Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms

BJU International

Volumn 94, Issue 9, 2004, Pages 1283-1286

  Laniado, Marc E ^a   Ockrim, Jeremy L ^a,c   Marronaro, Angelo ^b   Tubaro, Andrea ^b   Carter, Simon S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c WATFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

Diagnostic tests; Prostate specific antigen; Prostatic hyperplasia; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; URETHRA DISEASE; URINE FLOW RATE; URINE VOLUME; URODYNAMICS;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NECK OBSTRUCTION; URINARY RETENTION; URODYNAMICS;

EID: 11144221994     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05158.x     Document Type: Article

References (20)

1. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44
2. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410-5
3. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
4. Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. The PLESS Study Group. Urology 1999; 53: 473-80
5. Marberger MJ, Andersen JT, Nickel JC et al. Prostate Volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563-8
6. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. The Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63
7. Kirby R. Benign prostatic hyperplasia. BMJ 1999; 318: 343-4
8. Abrams P. Benign prostatic hyperplasia has precise meaning. BMJ 2001; 322: 106
9. Rodrigues P, Lucon AM, Freire GC, Arap S. Urodynamic pressure flow studies can predict the clinical outcome after transurethral prostatic resection. J Urol 2001; 165: 499-502
10. Javle P, Jenkins SA, Machin DG, Parsons KF. Grading of benign prostatic obstruction can predict the outcome of transurethral prostatectomy. J Urol 1998; 160: 1713-7
11. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Drug Safety 1998; 19: 45-55
12. Soomro NA, Neal DE. Adverse drug reactions in the urinary tract. Adverse Drug Reaction Bull 1998; 193: 735-8
13. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodynam 1997; 16: 1-18
14. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 1999; 84: 14-5
15. Jaeschke R, Guyatt GH, Sackett DL. Users's guide to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271: 703-7
16. Buchan I. StatsDirect Statistical Software. http://www.statsdirect.com. England: CamCode, 2001
17. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9
18. Reynard JM, Yang Q, Donovan JL et al. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82: 619-23
19. Madersbacher S, Klingler HC, Djavan B et al. Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol 1997; 80: 72-7
20. Roehrborn CG, Dolte KS, Ross KS, Girman G. Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. Urology 2000; 56: 9-18